Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

Healthcare Biotechnology
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

BELLUS Health Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by stockbond007on Dec 16, 2010 3:07pm
517 Views
Post# 17857791

BLU The real thing

BLU The real thing
If you guys did some dd you find out this is for real. check this out

On April 29, 2010, BELLUS Health entered into a strategic partnership with global pharmaceutical fund Celtic Therapeutic pursuant to which Celtic Therapeutics acquired and licensed worldwide rights related to KIACTA™ (eprodisate) and will fund 100% of KIACTA™’s development costs through its confirmatory Phase III clinical study and other development activities.  Celtic Therapeutics will also complete all other requirements for KIACTA™’s regulatory approval.

BLU was trading at above 25.00 in 2007 and with this kind of nr ( phase 111 ) this pharma stocks run fast and for a few days at the time.

The licence rights related to KIACTA is worldwide and has been acquired.

We will see more then a dollar very soon enjoy the  ride

Always do your dd

SB
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities